1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Hormone Sensitive Breast Cancer Global Clinical Trials Review, H1, 2016

Hormone Sensitive Breast Cancer Global Clinical Trials Review, H1, 2016

Summary

GlobalData's clinical trial report, “Hormone Sensitive Breast Cancer Global Clinical Trials Review, H1, 2016" provides an overview of Hormone Sensitive Breast Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Hormone Sensitive Breast Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Hormone Sensitive Breast Cancer Global Clinical Trials Review, H1, 2016
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Report Guidance 4
Clinical Trials by Region 5
Clinical Trials and Average Enrollment by Country 6
Top Countries Contributing to Clinical Trials in Asia-Pacific 8
Top Five Countries Contributing to Clinical Trials in Europe 9
Top Countries Contributing to Clinical Trials in North America 10
Top Countries Contributing to Clinical Trials in Middle East and Africa 11
Top Countries Contributing to Clinical Trials in Central and South America 12
Clinical Trials by G7 Countries: Proportion of Hormone Sensitive Breast Cancer to Oncology Clinical Trials 13
Clinical Trials by Phase in G7 Countries 14
Clinical Trials in G7 Countries by Trial Status 15
Clinical Trials by E7 Countries: Proportion of Hormone Sensitive Breast Cancer to Oncology Clinical Trials 16
Clinical Trials by Phase 17
In Progress Trials by Phase 18
Clinical Trials by Trial Status 19
Clinical Trials by End Point Status 20
Subjects Recruited Over a Period of Time 21
Clinical Trials by Sponsor Type 22
Prominent Sponsors 23
Top Companies Participating in Hormone Sensitive Breast Cancer Therapeutics Clinical Trials 24
Prominent Drugs 26
Clinical Trial Profile Snapshots 27
Appendix 70
Abbreviations 70
Definitions 70
Research Methodology 71
Secondary Research 71
About GlobalData 72
Contact Us 72
Disclaimer 72
Source 73

List of Tables
Hormone Sensitive Breast Cancer Therapeutics, Global, Clinical Trials by Region, 2016* 5
Hormone Sensitive Breast Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 6
Hormone Sensitive Breast Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 7
Hormone Sensitive Breast Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2016* 8
Hormone Sensitive Breast Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 9
Hormone Sensitive Breast Cancer Therapeutics Clinical Trials, North America, Top Countries, 2016* 10
Hormone Sensitive Breast Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 11
Hormone Sensitive Breast Cancer Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 12
Proportion of Hormone Sensitive Breast Cancer to Oncology Clinical Trials, G7 Countries (%), 2016* 13
Hormone Sensitive Breast Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 14
Hormone Sensitive Breast Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 15
Proportion of Hormone Sensitive Breast Cancer to Oncology Clinical Trials, E7 Countries (%), 2016* 16
Hormone Sensitive Breast Cancer Therapeutics, Global, Clinical Trials by Phase, 2016* 17
Hormone Sensitive Breast Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 18
Hormone Sensitive Breast Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2016* 19
Hormone Sensitive Breast Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2016* 20
Hormone Sensitive Breast Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 21
Hormone Sensitive Breast Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 22
Hormone Sensitive Breast Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 23
Hormone Sensitive Breast Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 25
Hormone Sensitive Breast Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 26

List of Figures
Hormone Sensitive Breast Cancer Therapeutics, Global, Clinical Trials by Region (%), 2016* 5
Hormone Sensitive Breast Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 6
Hormone Sensitive Breast Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 7
Hormone Sensitive Breast Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2016* 8
Hormone Sensitive Breast Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 9
Hormone Sensitive Breast Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 10
Hormone Sensitive Breast Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 11
Hormone Sensitive Breast Cancer Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 12
Proportion of Hormone Sensitive Breast Cancer to Oncology Clinical Trials, G7 Countries (%), 2016* 13
Hormone Sensitive Breast Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 14
Hormone Sensitive Breast Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 15
Proportion of Hormone Sensitive Breast Cancer to Oncology Clinical Trials, E7 Countries (%), 2016* 16
Hormone Sensitive Breast Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2016* 17
Hormone Sensitive Breast Cancer Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 18
Hormone Sensitive Breast Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2016* 19
Hormone Sensitive Breast Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2016* 20
Hormone Sensitive Breast Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 21
Hormone Sensitive Breast Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 22
Hormone Sensitive Breast Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 23
Hormone Sensitive Breast Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 24
Hormone Sensitive Breast Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 26
GlobalData Methodology 71

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Women’s Health Diagnostics Market by Application End User - Forecast to 2021

Women’s Health Diagnostics Market by Application End User - Forecast to 2021

  • $ 5650
  • Industry report
  • November 2016
  • by MarketsandMarkets

Women's Health Diagnostics Market by Application (Prenatal Testing, Down Syndrome, HPV, Fertility Test, Pregnancy Test, Urinary Tract Infections, Osteoporosis, Breast, Cervical and Ovarian Cancer Test) ...

Breast Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016

Breast Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016

  • $ 4000
  • Industry report
  • December 2016
  • by Global Data

Breast Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016 Summary GlobalData's Medical Devices sector report, “Breast Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016" ...

EpiCast Report: Breast Cancer (HER2+, HER2-) - Epidemiology Forecast to 2025

EpiCast Report: Breast Cancer (HER2+, HER2-) - Epidemiology Forecast to 2025

  • $ 3995
  • Industry report
  • December 2016
  • by Global Data

EpiCast Report: Breast Cancer (HER2+, HER2-) - Epidemiology Forecast to 2025 Summary Breast cancer is a malignant tumor that originates in the breast tissues. Most breast cancers are invasive tumors that ...


Download Unlimited Documents from Trusted Public Sources

Global Colorectal Cancer Statistics

  • January 2017
    4 pages
  • Colorectal Canc...  

  • Denmark  

    World  

View report >

Prostate Cancer and Cancer Statistics in the US

  • January 2017
    17 pages
  • Prostate Cancer  

    Cancer  

    Therapy  

  • United States  

View report >

Cancer Statistics in the US

  • January 2017
    16 pages
  • Cancer  

  • United States  

    World  

View report >

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.